Evolus is a beauty company focused on delivering products in the self-pay aesthetic market. Co.'s commercial product is Jeuveau® (prabotulinumtoxinA-xvfs), a proprietary purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Co.'s primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We show 25 historical shares outstanding datapoints in our EOLS shares outstanding history coverage, used to compute EOLS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EOLS market cap history over the course of time is important for investors
interested in comparing EOLS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EOLS versus a peer is one thing; comparing
EOLS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EOLS can fluctuate over the course of history.
With this page we aim to empower investors researching EOLS by allowing them to research the EOLS market cap history. |
Free EOLS Email Alerts:
Video: The Importance of Market Cap
